The radiopharmaceutical space saw a couple of huge deals at the end of last year, and another flurry, albeit on a rather smaller scale, happened this week. On September 12, both Sanofi and ITM Isotope Technologies Munich SE took licenses to promising technologies, coincidentally spending – or rather promising – a similar amount.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
